Atovaquone "chemical vaccine" for malaria could be more feas

Johns Hopkins researchers looking to develop a long-acting, injectable malaria preventive using atovaquone have shown in a new study that resistance may not be the challenge scientists thought it was, particularly when using atovaquone as a malaria preventive.

Related Keywords

, Rahul Bakshi , Johns Hopkins , Deborah Stiffler , Photini Sinnis , Andrew Owen , David Sullivan , Alexis Mann , Keyla Romero Rodriguez , Amanda Dziedzic , Elizabeth Nenortas , Sean Prigge , Matthew Canonizado , Abhai Tripathi , Anne Jedlicka , Lily Ramsey , Theresa Shapiro , Rubayet Elahi , Abeer Sayeed , World Health Organization , Johns Hopkins Malaria Research Institute , Johns Hopkins University School Of Medicine , Bloomberg School Department Of Molecular Microbiology , National Institutes Of Health , Bloomberg School , University Of Liverpool , W Harry Feinstone Department Of Molecular Microbiology , Johns Hopkins Bloomberg School Of Public Health , Nature Communications , Malaria Research Institute , Johns Hopkins University School , Johns Hopkins Bloomberg School , Clinical Pharmacology , Feinstone Department , Molecular Microbiology , Victoria Balta , Godfree Mlambo , Bloomberg Philanthropies , National Institutes , Malaria , Vaccine , Enetic , Mmunology , Liver , Medicine , Icrobiology , Mosquito , Utation , Reclinical , Public Health , Research ,